Cisplatin Plus Etoposide in the Adjuvant Treatment of Patients with Non Small Cell Lung Cancer
JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, cilt.5, sa.5, ss.414-416, 2014 (ESCI, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 5 Sayı: 5
- Basım Tarihi: 2014
- Doi Numarası: 10.4328/jcam.1469
- Dergi Adı: JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.414-416
- Bursa Uludağ Üniversitesi Adresli: Evet
Özet
Aim: In this study, the efficacy and safety of cisplatin and etoposide (PE) combination in the adjuvant treatment of patients with resected non-small cell lung cancer (NSCLC) was investigated. Material and Method: We retrospectively evaluated the medical charts of patients receiving adjuvant treatment for NSCLC at our center. Results: Forty-five patients were evaluated. The disease-free survival was 10 (1-114) months and the median overall survival was 18 (3-114) months. Discussion: Based on our limited experience, we concluded that PE regimen is safe and effective as adjuvant therapy for patients with NSCLC.